Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 5

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
  
    2024 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(34,197) 
    $(20,771)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Stock-based compensation 
     3,610  
     4,129 
  
    Accretion of debt discount 
     -  
     58 
  
    Impairment of acquired in-process research and development intangible assets 
     16,514  
     - 
  
    Changes in operating assets and liabilities: 

    Research and development tax credit receivable 
     (424) 
     (1,238)
  
    Other tax receivable 
     (322) 
     267 
  
    Prepaid expenses 
     (174) 
     497 
  
    Prepaid expenses – related party 
     -  
     142 
  
    Other assets 
     (491) 
     50 
  
    Accounts payable and accrued liabilities 
     1,132  
     1,381 
  
    Accounts payable and accrued liabilities – related parties 
     159  
     104 
  
    Deferred liabilities 
     (6) 
     32 
  
    Operating lease liabilities 
     -  
     (13)
  
    Net cash used in operating activities 
     (14,199) 
     (15,362)

    CASH FLOWS FROM INVESTING ACTIVITIES 

    Purchase of equipment 
     (706) 
     - 
  
    Net cash used in investing activities 
     (706) 
     - 

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Net proceeds from sale of common stock and warrants 
     27,544  
     15,497 
  
    Exercise of warrants for cash 
     1  
     - 
  
    Repayments of debt 
     -  
     (5,000)
  
    Net cash provided by financing activities 
     27,545  
     10,497 

    Impact on cash from foreign currency translation 
     (188) 
     86 

    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 
     12,452